Phase 1 study of the pharmacokinetics and clinical proof-of-concept activity of a biofilm-disrupting human monoclonal antibody in patients with chronic prosthetic joint infection of the knee or hip

• Published in: Antimicrobial agents and chemotherapy Vol. 68; no. 8; p. e0065524
• Main Authors: Conway, Janet, Delanois, Ronald E, Mont, Michael A, Stavrakis, Alexandra, McPherson, Edward, Stolarski, Edward, Incavo, Stephen, Oakes, Daniel, Salvagno, Ralph, Adams, John S, Kisch-Hancock, Adriane, Tenorio, Edgar, Leighton, Anton, Ryser, Stefan, Kauvar, Lawrence M, Bernthal, Nicholas M
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 07.08.2024
• Subjects: Aged; Anti-Bacterial Agents - pharmacokinetics; Anti-Bacterial Agents - pharmacology; Anti-Bacterial Agents - therapeutic use; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antimicrobial Chemotherapy; Biofilms - drug effects; Clinical Therapeutics; Double-Blind Method; Female; Humans; Male; Middle Aged; Prosthesis-Related Infections - drug therapy; Prosthesis-Related Infections - microbiology; antibiotic potentiation; monoclonal antibody; biofilm; prosthetic joint infection
• ISSN: 0066-4804; 1098-6596; 1098-6596
• DOI: 10.1128/aac.00655-24

We report the results of a first-in-human phase 1 clinical study to evaluate TRL1068, a native human monoclonal antibody that disrupts bacterial biofilms with broad-spectrum activity against both Gram-positive and Gram-negative species. The study population consisted of patients with chronic periprosthetic joint infections (PJIs) of the knee or hip, including both monomicrobial and polymicrobial infections, that are highly resistant to antibiotics due to biofilm formation. TRL1068 was administered via a single pre-surgical intravenous infusion in three sequentially ascending dose groups (6, 15, and 30 mg/kg). Concomitant perioperative antibiotics were pathogen-targeted as prescribed by the treating physician. In this double-blinded study, 4 patients were randomized to receive placebo and 11 patients to receive TRL1068 on day 1, as well as targeted antibiotics for 7 days prior to the scheduled removal of the infected implant and placement of an antibiotic-eluting spacer as the first stage of the standard of care two-stage exchange arthroplasty. No adverse events attributable to TRL1068 were reported. TRL1068 serum half-life was 15-18 days. At day 8, the concentration in synovial fluid was approximately 60% of the blood level and thus at least 15-fold above the threshold for biofilm-disrupting activity . Explanted prostheses were sonicated to release adherent bacteria for culture, with elimination of the implant bacteria observed in 3 of the 11 patients who received TRL1068, which compares favorably to prior PJI treatments. None of the patients who received TRL1068 had a relapse of the original infection by the end of the study (day 169). This study is registered with ClinicalTrials.gov as NCT04763759.